Dr. Michael Soulen discusses safety concerns and adverse events in neuroendocrine tumor treatments, highlighting cytopenia and radiation risks while ensuring patient safety.
Michael Soulen, MD
Advertisement
Michael Soulen, MD, is the director of Interventional Oncology at the Abramson Cancer Center at the University of Pennsylvania
Articles by Michael Soulen, MD
A novel treatment combining chemotherapy and PRRT shows promising safety and efficacy for neuroendocrine tumors, with high response rates and ongoing trials.
Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT.
New research compares transarterial embolization and chemoembolization for treating neuroendocrine liver metastases, revealing unexpected safety differences.
Advertisement
Latest Updated Articles
RETNET: Exploring Therapies for Liver Metastases in NETsPublished: October 24th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
5
